CTD-ILD的研究进展
Advances in CTD-ILD Research
摘要: 间质性肺病(ILDs)是一组主要影响肺实质、间质的异质性肺疾病，主要的异常特征是炎症细胞和间充质细胞的病理性积累。结缔组织疾病(CTD)是一种广泛的影响不同器官的系统性自身免疫性疾病。由于感染、药物毒性、淋巴细胞增生性疾病或肿瘤疾病，肺部可主要或继发地受到影响，与免疫功能正常的人群相比，这些疾病在CTD患者中更常见。间质性肺疾病(ILD)可发生于所有的结缔组织疾病(CTD)，CTD-ILD是一种导致肺间质异常或肺纤维化的系统性自身免疫性疾病的集合，是导致患者病情加重和死亡的主要原因之一，其中类风湿性关节炎的ILD总患病率为11%，系统性硬化症为47%，特发性炎性肌炎为41%，原发性Sjogren综合征为17%，混合性结缔组织病为56%，系统性红斑狼疮为6%，通常间质性肺炎是类风湿性关节炎中最常见的ILD类型(总患病率为46%)，而非特异性间质性肺炎是所有其他CTD亚型中最常见的ILD类型(总患病率范围为27%~76%)。CTD-ILD是近年来ILD领域进展很大的领域，越来越多该方面的研究被发表，本综述系统复习了2019年4月至2023年4月国外权威杂志中关于“CTD和CTD-ILD”方面的文献，总结了对CTD-ILD方面研究的进展。
Abstract: Interstitial lung diseases (ILDs) are a heterogeneous group of lung diseases that primarily affect the lung parenchyma and interstitium, with the main abnormalities characterized by pathological ac-cumulation of inflammatory and mesenchymal cells. Connective tissue diseases (CTDs) are a broad spectrum of systemic autoimmune diseases affecting different organs. The lungs can be affected primarily or secondarily due to infections, drug toxicity, lymphoproliferative disorders, or neo-plastic diseases, which are more common in patients with CTDs than in immunocompetent popula-tions. Interstitial lung disease (ILD) can occur in all connective tissue diseases (CTDs). CTD-ILD is a collection of systemic autoimmune disorders that result in interstitial abnormalities or pulmonary fibrosis, and is one of the leading causes of exacerbation and death in patients. The overall preva-lence of ILD is 11% in rheumatoid arthritis, 47% in systemic sclerosis, idiopathic inflammatory myositis 41%, primary Sjogren’s syndrome 17%, mixed connective tissue disease 56%, and sys-temic lupus erythematosus 6%. Usually, interstitial pneumonia is the most common type of ILD in rheumatoid arthritis (total prevalence 46%), and nonspecific interstitial pneumonia is the most common type of ILD among all other CTD subtypes (total prevalence range 27%~76%). CTD-ILD is an area of great progress in the field of ILD in recent years, and more and more studies in this area have been published. This review systematically reviewed the literature on “CTD and CTD-ILD” in overseas refereed journals from April 2019 to April 2023, and summarized the progress of research on CTD-ILD. The review summarizes the progress of research on CTD-ILD.
文章引用：武玲玲, 刘洪千. CTD-ILD的研究进展[J]. 临床医学进展, 2023, 13(9): 13980-139880. https://doi.org/10.12677/ACM.2023.1391955

参考文献

[1] Spagnolo, P., Distler, O., Ryerson, C.J., Tzouvelekis, A., Lee, J.S., Bonella, F., Bouros, D., Hoffmann-Vold, A.M., Crestani, B. and Matteson, E.L. (2021) Mechanisms of Progressive Fibrosis in Connective Tissue Disease (CTD)-Associated Interstitial Lung Diseases (ILDs). Annals of the Rheumatic Diseases, 80, 143-150. [Google Scholar] [CrossRef] [PubMed]
[2] Cerro Chiang, G. and Parimon, T. (2023) Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers. International Journal of Molecular Sciences, 24, Article 2405. [Google Scholar] [CrossRef] [PubMed]
[3] Joy, G.M., Arbiv, O.A., Wong, C.K., Lok, S.D., Adderley, N.A., Dobosz, K.M., Johannson, K.A. and Ryerson, C.J. (2023) Prevalence, Imaging Patterns and Risk Factors of Interstitial Lung Disease in Connective Tissue Disease: A Systematic Review and Meta-Analysis. European Respiratory Review, 32, Article ID: 220210. [Google Scholar] [CrossRef] [PubMed]
[4] Jee, A.S. and Corte, T.J. (2019) Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs, 79, 1511-1528. [Google Scholar] [CrossRef] [PubMed]
[5] Jee, A.S., Sheehy, R., Hopkins, P., Corte, T.J., Grainge, C., Troy, L.K., Symons, K., Spencer, L.M., Reynolds, P.N., Chapman, S., de Boer, S., Reddy, T., Holland, A.E., Chambers, D.C., Glaspole, I.N., Jo, H.E., Bleasel, J.F., Wrobel, J.P., Dowman, L., Parker, M.J.S., Wilsher, M.L., Goh, N.S.L., Moodley, Y. and Keir, G.J. (2021) Diagnosis and Management of Connective Tissue Disease-Associated Interstitial Lung Disease in Australia and New Zealand: A Position Statement from the Thoracic Society of Australia and New Zea-land. Respirology, 26, 23-51. [Google Scholar] [CrossRef] [PubMed]
[6] Oldham, J.M., Lee, C.T., Wu, Z., Bowman, W.S., Pugashetti, J.V., Dao, N., Tonkin, J., Seede, H., Echt, G., Adegunsoye, A., Chua, F., Maher, T.M., Garcia, C.K., Strek, M.E., Newton, C.A. and Molyneaux, P.L. (2022) Lung Function Trajectory in Progressive Fibrosing Interstitial Lung Disease. European Respiratory Journal, 59, Article ID: 2101396. [Google Scholar] [CrossRef] [PubMed]
[7] Zheng, B., Donohoe, K., Hambly, N., Johannson, K.A., As-sayag, D., Fisher, J.H., Manganas, H., Marcoux, V., Khalil, N., Kolb, M. and Ryerson, C.J. (2022) Clinical Relevance of Rheumatoid Factor and Anti-Citrullinated Peptides in Fibrotic Interstitial Lung Disease. Respirology, 27, 854-862. [Google Scholar] [CrossRef] [PubMed]
[8] Zheng, J.N., Li, Y., Yan, Y.M., Yu, Y., Shao, W.Q. and Wang, Q. (2020) Increased Serum Calpain Activity Is Associated with HMGB1 Levels in Systemic Sclerosis. Arthritis Research & Ther-apy, 22, Article No. 110. [Google Scholar] [CrossRef] [PubMed]
[9] Lee, J.S., Lee, E.Y., Ha, Y.J., Kang, E.H., Lee, Y.J. and Song, Y.W. (2019) Serum KL-6 Levels Reflect the Severity of Interstitial Lung Disease Associated with Connective Tissue Disease. Arthritis Research & Therapy, 21, Article No. 58. [Google Scholar] [CrossRef] [PubMed]
[10] Meng, K., Tian, M., Gui, X., Xie, M., Gao, Y., Shi, S., Zhao, T., Xiao, Y., Cai, H. and Ding, J. (2022) Human Epididymis Protein 4 Is Associated with Severity and Poor Prognosis of Connective Tissue Disease-Associated Interstitial Lung Disease with Usual Interstitial Pneumonia Pattern. International Immunopharmacology, 108, Article ID: 108704. [Google Scholar] [CrossRef] [PubMed]
[11] Hoffmann, T., Oelzner, P., Franz, M., Teichgräber, U., Renz, D., Förster, M., Böttcher, J., Kroegel, C., Schulze, P.C., Wolf, G. and Pfeil, A. (2022) Assessing the Diagnostic Value of a Potential Screening Tool for Detecting Early Interstitial Lung Disease at the Onset of Inflammatory Rheumatic Diseases. Arthritis Research & Therapy, 24, Article No. 107. [Google Scholar] [CrossRef] [PubMed]
[12] Wang, Y., Xie, X., Zheng, S., Du, G., Chen, S., Zhang, W., Zhuang, J., Lin, J., Hu, S., Zheng, K., Mikish, A., Xu, Z., Zhang, G., Gargani, L., Bruni, C., Hoffmann-Vold, A.M., Matucci-Cerinic, M. and Furst, D.E. (2022) Serum B-Cell Activating Factor and Lung Ultrasound B-Lines in Connective Tissue Disease Related Interstitial Lung Disease. Frontiers in Medi-cine, 9, Article 1066111. [Google Scholar] [CrossRef] [PubMed]
[13] Xie, H.Q., Zhang, W.W., Sun, S., Chen, X.M., Yuan, S.F., Gong, Z.H. and Liu, L. (2019) A Simplified Lung Ultrasound for the Diagnosis of Interstitial Lung Disease in Connective Tissue Disease: A Meta-Analysis. Arthritis Research & Therapy, 21, Article No. 93. [Google Scholar] [CrossRef] [PubMed]
[14] Jiang, X., Su, N., Quan, S., E, L. and Li, R. (2023) Computed Tomography Radiomics-Based Prediction Model for Gender-Age-Physiology Staging of Connective Tissue Dis-ease-Associated Interstitial Lung Disease. Academic Radiology. [Google Scholar] [CrossRef] [PubMed]
[15] Broens, B., Duitman, J.W., Zwezerijnen, G.J.C., Nossent, E.J., van der Laken, C.J. and Voskuyl, A.E. (2022) Novel Tracers for Molecular Imaging of Interstitial Lung Disease: A State of the Art Review. Autoimmunity Reviews, 21, Article ID: 103202. [Google Scholar] [CrossRef] [PubMed]
[16] Hata, K., Yanagihara, T., Matsubara, K., Kunimura, K., Suzuki, K., Tsubouchi, K., Eto, D., Ando, H., Uehara, M., Ikegame, S., Baba, Y., Fukui, Y. and Okamoto, I. (2023) Mass Cy-tometry Identifies Characteristic Immune Cell Subsets in Bronchoalveolar Lavage Fluid from Interstitial Lung Diseases. Frontiers in Immunology, 14, Article 1145814. [Google Scholar] [CrossRef] [PubMed]
[17] Rzepka-Wrona, P., Skoczyński, S. and Barczyk, A. (2022) Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study. International Journal of Molecular Sciences, 23, Article 15205. [Google Scholar] [CrossRef] [PubMed]
[18] Weng, L., Liu, W., Wang, L., Wu, Z., Liu, D., Lin, Y., Song, S., Yu, C., Chen, Y., Chen, J. and Ge, S. (2022) Serum MUC5AC Protein Levels Are Correlated with the Development and Se-verity of Connective Tissue Disease-Associated Pulmonary Interstitial Lesions. Frontiers in Immunology, 13, Article 987723. [Google Scholar] [CrossRef] [PubMed]
[19] Romero-Bueno, F.I., Rodríguez-Nieto, M.J., Palacios Miras, C., Martínez Estupiñán, L., Martínez-Becerra, M.J., Vegas Sánchez, M.C., Cedeño Díaz, O.M. and Sánchez-Pernaute, O. (2023) Fine-Tuning Characterization of Patients with Interstitial Pneumonia and an Underlying Autoimmune Disease in Real-World Practice: We Get Closer with Nailfold Videocapillaroscopy. Frontiers in Medicine, 10, Article 1057643. [Google Scholar] [CrossRef] [PubMed]
[20] Dsouza, K.G., Surolia, R., Kulkarni, T., Li, F.J., Singh, P., Zeng, H., Stephens, C., Kumar, A., Wang, Z. and Antony, V.B. (2023) Use of a Pulmosphere Model to Evaluate Drug Antifi-brotic Responses in Interstitial Lung Diseases. Respiratory Research, 24, Article No. 96. [Google Scholar] [CrossRef] [PubMed]
[21] Graham, J., Bauer Ventura, I., Newton, C.A., Lee, C., Boctor, N., Pugashetti, J.V., Cutting, C., Joerns, E., Sandhu, H., Chung, J.H., Garcia, C.K., Kadoch, M., Noth, I., Adegunsoye, A., Strek, M.E. and Oldham, J.M. (2020) Myositis-Specific Antibodies Identify A Distinct Interstitial Pneumonia with Au-toimmune Features Phenotype. European Respiratory Journal, 56, Article ID: 2001205. [Google Scholar] [CrossRef] [PubMed]
[22] Xu, L., Wang, F. and Luo, F. (2022) Rituximab for the Treat-ment of Connective Tissue Disease-Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 13, Article 1019915. [Google Scholar] [CrossRef] [PubMed]
[23] Maher, T.M., Tudor, V.A., Saunders, P., Gibbons, M.A., Fletch-er, S.V., Denton, C.P., Hoyles, R.K., Parfrey, H., Renzoni, E.A., Kokosi, M., Wells, A.U., Ashby, D., Szigeti, M. and Molyneaux, P.L. (2023) Rituximab versus Intravenous Cyclophosphamide in Patients with Connective Tissue Dis-ease-Associated Interstitial Lung Disease in the UK (RECITAL): A Double-Blind, Double-Dummy, Randomised, Con-trolled, Phase 2b Trial. The Lancet Respiratory Medicine, 11, 45-54.
[24] Liossis, S.C. and Bounia C.A., (2022) Treat-ing Autoimmune-Related Interstitial Lung Disease with B Cell Depletion. Frontiers in Medicine, 9, Article 937561. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, J., Wang, X., Qi, X., Sun, Z., Zhang, T., Cui, Y. and Shu, Q. (2022) The Efficacy and Safety of Pirfenidone Combined with Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study. Frontiers in Medicine, 9, Article 871861. [Google Scholar] [CrossRef] [PubMed]
[26] Deng, L., Chen, Y., Hu, X., Zhou, J. and Zhang, Y. (2021) Case Report: Successful Treatment of Refractory Interstitial Lung Disease with Cyclosporine A and Pirfenidone in a Child with SLE. Frontiers in Immunology, 12, Article 708463. [Google Scholar] [CrossRef] [PubMed]
[27] Yin, X., Zhao, S., Xiang, N., Chen, J., Xu, J. and Zhang, Y. (2023) Efficacy and Safety of Chinese Herbal Medicines Combined with Cyclophosphamide for Connective Tissue Dis-ease-Associated Interstitial Lung Disease: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacolo-gy, 14, Article 1064578. [Google Scholar] [CrossRef] [PubMed]
[28] Li, Y., Zhu, W., He, H., Garov, Y.A., Bai, L., Zhang, L., Wang, J., Wang, J. and Zhou, X. (2021) Efficacy and Safety of Tripterygium Wilfordii Hook. F for Connective Tissue Dis-ease-Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 12, Ar-ticle 691031. [Google Scholar] [CrossRef] [PubMed]
[29] Zhu, W., Wang, Y., Liu, C., Wu, Y., Li, Y. and Wang, Y. (2022) Connective Tissue Disease-Related Interstitial Lung Disease Is Alleviated by Tripterine through Inhibition of the PI3K/Akt, Apoptosis, and TNF-α Signalling Pathways. Frontiers in Pharmacology, 13, Article 990760. [Google Scholar] [CrossRef] [PubMed]
[30] Liu, Y., Hu, M., Fan, G., Xing, N. and Zhang, R. (2022) Effect of Baricitinib on the Epithelial-Mesenchymal Transition of Alveolar Epithelial Cells Induced by IL-6. International Im-munopharmacology, 110, Article ID: 109044. [Google Scholar] [CrossRef] [PubMed]
[31] Tomassetti, S., Ravaglia, C., Puglisi, S., Wells, A.U., Ryu, J.H., Bosi, M., Dubini, A., Piciucchi, S., Girelli, F., Parronchi, P., Lavorini, F., Rosi, E., Luzzi, V., Cerinic, M.M. and Poletti, V. (2023) Clinical Implications of Interstitial Pneumonia with Autoimmune Features Diagnostic Criteria in Idiopathic Pulmonary Fibrosis: A Case Control Study. Frontiers in Medicine, 10, Article 1087485. [Google Scholar] [CrossRef] [PubMed]
[32] Natalini, J.G., Diamond, J.M., Porteous, M.K., Lederer, D.J., Wille, K.M., Weinacker, A.B., Orens, J.B., Shah, P.D., Lama, V.N., McDyer, J.F., Snyder, L.D., Hage, C.A., Singer, J.P., Ware, L.B., Cantu, E., Oyster, M., Kalman, L., Christie, J.D., Kawut, S.M. and Bernstein, E.J. (2021) Risk of Pri-mary Graft Dysfunction following Lung Transplantation in Selected Adults with Connective Tissue Disease-Associated Interstitial Lung Disease. The Journal of Heart and Lung Transplantation, 40, 351-358. [Google Scholar] [CrossRef] [PubMed]
[33] Zhang, N., Liu, S., Zhang, Z., Liu, Y., Mi, L. and Xu, K. (2023) Lung Transplantation: A Viable Option for Connective Tissue Disease? Arthritis Care & Research. [Google Scholar] [CrossRef] [PubMed]
[34] Gao, Y., Zhao, Q., Qiu, X., Zhuang, Y., Yu, M., Dai, J., Cai, H. and Yan, X. (2020) Vitamin D Levels Are Prognostic Factors for Connective Tissue Disease Associated Interstitial Lung Disease (CTD-ILD). Aging, 12, 4371-4378. [Google Scholar] [CrossRef] [PubMed]
[35] Chiu, Y.H., Koops, M.F.M., Voortman, M., van Es, H.W., Langezaal, L.C.M., Welsing, P.M.J., Jamnitski, A., Wind, A.E., van Laar, J.M., Grutters, J.C. and Spierings, J. (2023) Prognostica-tion of Progressive Pulmonary Fibrosis in Connective Tissue Disease-Associated Interstitial Lung Diseases: A Cohort Study. Frontiers in Medicine, 10, Article 1106560. [Google Scholar] [CrossRef] [PubMed]
[36] Nagy, A., Nagy, T., Kolonics-Farkas, A.M., Eszes, N., Vincze, K., Barczi, E., Tarnoki, A.D., Tarnoki, D.L., Nagy, G., Kiss, E., Maurovich-Horvat, P., Bohacs, A. and Müller, V. (2021) Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline. Frontiers in Pharmacology, 12, Article 778649. [Google Scholar] [CrossRef] [PubMed]

为你推荐